Key result
EMPOWER CAD evaluates Shockwave coronary intravascular lithotripsy safety and procedural success in female patients.
Why the study?
Coronary artery disease is the leading cause of death in women, who experience worse PCI outcomes and complex calcified anatomy, yet remain underrepresented in interventional CAD clinical trials.
Does the Shockwave Coronary intravascular lithotripsy (IVL) system improve procedural success and safety in female patients with calcified coronary artery disease undergoing PCI?
Observational (n=400)
Yes
Does the Shockwave Coronary intravascular lithotripsy (IVL) system improve procedural success and safety in female patients with calcified coronary artery disease undergoing PCI?
The EMPOWER CAD study is a prospective, single-arm observational study designed to evaluate the safety and effectiveness of coronary intravascular lithotripsy specifically in women with calcified coronary artery disease.
Answers are grounded in this paper and cite their sources.
Prospective data on coronary IVL in women forthcoming; leaves open comparative effectiveness versus other calcium-modification strategies.
Background: Coronary artery disease (CAD) is the leading cause of death for women, yet they remain underrepresented in interventional CAD studies. Women have been shown to be at increased risk of mortality and major adverse events after percutaneous coronary intervention (PCI). The poorer outcomes are likely because women are typically diagnosed with CAD late, at an older age, with more comorbidities, and with more challenging anatomy including smaller vessels and higher prevalence of coronary artery calcification. Methods: The EMPOWER CAD study (NCT05755711) is a postmarket, prospective, multicenter, single-arm observational study of the Shockwave Coronary intravascular lithotripsy (IVL) system for the treatment of women with calcified coronary artery disease. The study will enroll 400 female patients referred for PCI with coronary IVL and stenting. The primary safety end point is target lesion failure (TLF) at 30 days, defined as a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. The primary effectiveness end point is procedural success, defined as stent delivery with a residual in-stent stenosis ≤30% in all target lesions and without in-hospital TLF as assessed by an independent core laboratory and clinical events committee. Patients will be followed up for 3 years. Conclusions: The EMPOWER CAD study will enroll real-world female patients. Adjunctive use of IVL with other calcium modification technologies will be assessed, as well as a subcohort analysis of patients with optical coherence tomography imaging. The EMPOWER CAD study therefore directly addresses the underrepresentation of women in interventional cardiology clinical trials.
No takes yet. Share an insight, caveat, or question.
McEntegart et al. (2024) conducted an observational in Calcified coronary artery disease (n=400). Shockwave Coronary intravascular lithotripsy (IVL) system was evaluated on Target lesion failure at 30 days (safety) and procedural success (effectiveness). The EMPOWER CAD study is a prospective, single-arm observational study designed to evaluate the Shockwave Coronary intravascular lithotripsy system in 400 female patients.
Synapse has enriched 10 related papers. Consider them for comparative context: